FRAMINGHAM, MA — At ASMS 2023, SCIEX, a global leader in life science analytical technologies, launches the Intabio ZT system, the first fully-integrated microfluidic chip-based platform combining imaged capillary isoelectric focusing (icIEF) separation and UV detection. When coupled with mass spectrometry (MS) identification on the ZenoTOF 7600 system, it eliminates the guesswork from early drug development stages and accelerates drug candidate selection. This icIEF-UV/MS workflow enables separation, quantitation, and identification of biopharmaceutical charge variants and their proteoforms.
The Intabio ZT system can acquire data on charge isoforms for biopharmaceuticals in minutes instead of weeks. This capability targets a key bottleneck in biopharmaceutical characterization, where lack of connectivity between cIEF and MS assays can hamper the identification of unknown peaks early in the development process. The Intabio ZT system also harnesses the sophisticated data processing capability within Biologics Explorer software to unlock a new depth of information.
“We hear from customers the consistent need to identify developable molecules earlier in the process. To do so, we need multiple pieces of critical data up front. The Intabio ZT system provides mass information on charge variants that has the power to change protein therapeutic development by providing the comprehensive data needed to make quick and confident decisions on the developability of potential therapies,” said Dom Gostick, Vice President of Product Management at SCIEX.